Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.49 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090648 | 0.88 | AVPR1A (0.58) | CYP2D6AVPR1AC5AR1CACNA1GCACNA1H | |
| SCHEMBL27714484 | 0.81 | AVPR1A (0.52) | CYP2D6AVPR1AAVPR2POLB | |
| SCHEMBL3098913 | 0.79 | OPRM1 (0.59) | AVPR1ACYP3A4OPRM1OPRL1 | |
| SCHEMBL3566545 | 0.78 | AVPR1A (0.67) | AVPR1AAVPR2POLB | |
| SCHEMBL3093920 | 0.78 | AVPR1A (0.56) | AVPR1AAVPR2POLB | |
| SCHEMBL3087495 | 0.75 | AVPR1A (0.51) | AVPR1AAVPR2POLBOPRM1OPRL1 | |
| SCHEMBL4683069 | 0.74 | CYP2D6 (0.66) | CYP2D6C5AR1CACNA1GCACNA1HCYP3A4 | |
| SCHEMBL3091896 | 0.74 | AVPR1A (0.52) | CYP2D6AVPR1AAVPR2POLBOPRM1 | |
| SCHEMBL9985461 | 0.74 | AVPR1A (0.61) | AVPR1AAVPR2POLB | |
| SCHEMBL10265794 | 0.74 | AVPR1A (0.69) | AVPR1AAVPR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803815-B2 | Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | claimed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | claimed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | claimed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | BISSANTZ CATERINA | 2010-10-07 | — | — | US | disclosed |
| US-7803815-B2 | Indol-3-yl-corbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256140-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES | AVPR1A, AVPR2, AVPR1B | CYP2D6 2432/4885AVPR1A 1/4885C5AR1 1481/4885 |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | AVPR1A, AVPR2, AVPR1B | CYP2D6 2432/4885AVPR1A 1/4885C5AR1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.